XOMA (NASDAQ:XOMA) Given New $104.00 Price Target at HC Wainwright

XOMA (NASDAQ:XOMA) had its target price reduced by HC Wainwright from $123.00 to $104.00 in a report issued on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a report on Thursday, January 16th.

XOMA Price Performance

Shares of NASDAQ XOMA opened at $24.88 on Monday. The stock has a market capitalization of $293.09 million, a price-to-earnings ratio of -7.15 and a beta of 0.90. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 52 week low of $19.50 and a 52 week high of $35.00. The firm has a 50-day simple moving average of $27.72 and a 200-day simple moving average of $28.07.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $7.20 million during the quarter, compared to the consensus estimate of $6.66 million. On average, equities analysts predict that XOMA will post -1.41 earnings per share for the current fiscal year.

Insider Activity at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Owen Hughes sold 21,881 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the sale, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in XOMA. BNP Paribas Financial Markets lifted its holdings in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares during the period. New York State Common Retirement Fund grew its holdings in XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 800 shares during the last quarter. Rhumbline Advisers increased its position in XOMA by 18.1% during the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 1,699 shares in the last quarter. Barclays PLC lifted its stake in shares of XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares during the period. Finally, Ellsworth Advisors LLC purchased a new position in XOMA during the third quarter worth about $516,000. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.